People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Healthtech, Other Health Care, Other, Software / Tech, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Monogram Health Holdings, Inc. | — | Healthtech | Series D+ | $535.1M | $5.5B | 2021 |
| Route 92 Medical, Inc. | — | Healthtech | Series C | $158.1M | $428.8M | 2021 |
| Omada Health, Inc. | — | Other Health Care | Series C | $71.5M | $1.1B | 2015 |
| BASIS Science, Inc. | — | Other | Series B | $43.8M | $387.0M | 2013 |
| NextHealth Technologies, Inc. | — | Software / Tech | Series B | $30.3M | $60.1M | 2016 |
| DeVoro Medical Inc. | — | Healthtech | Series B | $26.5M | $446.1M | 2020 |
| AtheroMed Inc | — | Other Health Care | Series A | $24.7M | $87.7M | 2009 |
| Simpirica Spine, Inc. | — | Other Technology | Series A | $20.0M | $138.7M | 2013 |
| Monogram Health, Inc. | — | Healthtech | Series A | $12.0M | $158.0M | 2019 |
Casper De Clercq at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Casper De Clercq on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Tony Chou | 3 | 7 |
| Jonathan Root | 2 | 16 |
| William Frist | 2 | 10 |
| Christopher Booker | 2 | 5 |
| CHRIS CHI | 2 | 2 |
| Michael Uchrin | 2 | 2 |
| Richard Ferrari | 1 | 15 |
| Casey Tansey | 1 | 14 |
| Jason Krikorian | 1 | 12 |
| David Mauney | 1 | 10 |
| David Klein | 1 | 10 |
| Tim Chang | 1 | 9 |
| Kendall Garrison | 1 | 7 |
| Jack Lasersohn | 1 | 5 |
| Tamir Meiri | 1 | 5 |
| Michael Wallace | 1 | 5 |
| Balaji Srinivasan | 1 | 4 |
| David Schulte | 1 | 4 |
| Erik Engelson | 1 | 4 |
| Ken Ludlum | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.